Literature DB >> 20547999

Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.

Paul J Kelly1, Stephanie E Weiss, David J Sher, Antonio R Perez-Atayde, Paola Dal Cin, Toni K Choueiri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20547999     DOI： 10.1200/JCO.2009.26.8193

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

Review 1.  Treatment of brain metastases: chemotherapy.

Authors:  Sean A Grimm
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

Review 2.  Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Authors:  Philip Wong; Peter Houghton; David G Kirsch; Steven E Finkelstein; Arta M Monjazeb; Meng Xu-Welliver; Adam P Dicker; Mansoor Ahmed; Bhadrasain Vikram; Beverly A Teicher; C Norman Coleman; Mitchell Machtay; Walter J Curran; Dian Wang
Journal:  J Natl Cancer Inst       Date:  2014-10-18       Impact factor: 13.506

Review 3.  Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.

Authors:  Jacob Ruzevick; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Neurosurg Rev       Date:  2013-11-15       Impact factor: 3.042

Review 4.  Combining radiotherapy with sunitinib: lessons (to be) learned.

Authors:  Esther A Kleibeuker; Matthijs A Ten Hooven; Henk M Verheul; Ben J Slotman; Victor L Thijssen
Journal:  Angiogenesis       Date:  2015-07-23       Impact factor: 9.596

5.  Pazopanib-Induced Regression of Brain Metastasis After Whole Brain Palliative Radiotherapy in Metastatic Renal Cell Cancer Progressing on First-Line Sunitinib: A Case Report.

Authors:  Mohan Hingorani; Sanjay Dixit; Anthony Maraveyas
Journal:  World J Oncol       Date:  2014-12-03

6.  Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?

Authors:  Dong Ho Lee; Sangyoun Hwang; Young Hwan Koh; Kyung-Hun Lee; Ju Yeon Kim; Yoon Jun Kim; Jung-Hwan Yoon; Jeong-Hoon Lee; Joong-Won Park
Journal:  Front Med (Lausanne)       Date:  2021-12-13

7.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.